Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
BLSM · Why this verdict
Why BlossomHill Therapeutics (BLSM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
BlossomHill is a pre-revenue, loss-making biotech whose case rests on heavy insider buying and a 128% gap to the analyst target, offset by weak quality, falling momentum and a near-term earnings event.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The $30.80 analyst target sits 128.1% above the $13.50 price, implying the market heavily discounts the pipeline relative to analyst views. Sentiment breakdown | The price should close a meaningful part of the gap to the target as clinical data arrives. | ↓Deteriorating |
| CounterBiotech analyst targets assume trial success; with a 52% drawdown from the high the market may be pricing real failure risk. | ||
Business quality is weak (quality score 2.9 versus a 4.0 floor) with operating margin of -39.6% and no revenue in recent quarters. Bear case | Losses should stay funded without dilution as the company advances its programs. | →Stable |
| CounterA pre-revenue company burning cash must raise capital, and dilution could erase the upside from any success. | ||
Insiders bought about $25.1M of stock (5.859% of market cap) across 6 purchases with zero sales in 90 days, a strong conviction signal for a $0.4B company. Insider breakdown | Insider buying should persist or insiders should hold their positions, with no net selling over the next 12 months. | →Stable |
| CounterInsider purchases in a cash-burning biotech may be financing-related participation and do not guarantee clinical success. | ||
Momentum is poor, with a momentum score of 2.9 and volume distribution shown by falling OBV, so sellers currently dominate. Momentum breakdown | Momentum should recover above 4.5 and OBV should stop falling if the base is forming. | ↓Deteriorating |
| CounterThe price is only mid-range (RSI 47) and a downtrend with distribution can continue to new lows ahead of a binary event. | ||
The last reported quarter was a large miss ($-8.75 actual versus $-0.77 estimated) and the next report arrives in 8 days on 2026-11-16. Earnings | Quarterly losses per share should land near or better than consensus, without a further surprise. | ↑Improving |
| CounterBiotech EPS estimates are unreliable due to lumpy R&D and one-time charges, so another large deviation is plausible. | ||
The $30.80 analyst target sits 128.1% above the $13.50 price, implying the market heavily discounts the pipeline relative to analyst views.
↓DeterioratingSentiment breakdown
- Expectation
- The price should close a meaningful part of the gap to the target as clinical data arrives.
CounterBiotech analyst targets assume trial success; with a 52% drawdown from the high the market may be pricing real failure risk.
Business quality is weak (quality score 2.9 versus a 4.0 floor) with operating margin of -39.6% and no revenue in recent quarters.
→StableBear case
- Expectation
- Losses should stay funded without dilution as the company advances its programs.
CounterA pre-revenue company burning cash must raise capital, and dilution could erase the upside from any success.
Insiders bought about $25.1M of stock (5.859% of market cap) across 6 purchases with zero sales in 90 days, a strong conviction signal for a $0.4B company.
→StableInsider breakdown
- Expectation
- Insider buying should persist or insiders should hold their positions, with no net selling over the next 12 months.
CounterInsider purchases in a cash-burning biotech may be financing-related participation and do not guarantee clinical success.
Momentum is poor, with a momentum score of 2.9 and volume distribution shown by falling OBV, so sellers currently dominate.
↓DeterioratingMomentum breakdown
- Expectation
- Momentum should recover above 4.5 and OBV should stop falling if the base is forming.
CounterThe price is only mid-range (RSI 47) and a downtrend with distribution can continue to new lows ahead of a binary event.
The last reported quarter was a large miss ($-8.75 actual versus $-0.77 estimated) and the next report arrives in 8 days on 2026-11-16.
↑ImprovingEarnings
- Expectation
- Quarterly losses per share should land near or better than consensus, without a further surprise.
CounterBiotech EPS estimates are unreliable due to lumpy R&D and one-time charges, so another large deviation is plausible.
Per-dimension breakdown
Quality
2.9/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.6 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 2.6 |
| OBV | 1.0 |
| MA position | 2.5 |
| Volume | 4.1 |
- ▸Volume distribution (falling OBV)
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 162%
Insider
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $25,142,400 (5.859% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.9 |
| support resistance | 6.6 |
| 52w position | 0.0 |
Risk (lower is worse)
5.9/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 8.8 |
| volatility | 0.0 |
| debt equity | 8.9 |
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings in 8 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- ASYMMETRY:8.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.9<4.5
Warning (1)
- EARNINGS_PROXIMITY:8d<=14d (soft)
Reward-to-Risk
8.54
Upside
+128.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 47 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Drawdown -52% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.9<4.5 outcome against Value at 9.0 and asymmetric R:R of 8.54.
The strongest dimensions are Value at 9.0, Insider at 8.5, and Sentiment at 6.6; the weakest are Catalyst at 2.5, Momentum at 2.9, and Quality at 2.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 8.54 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying Conviction
Trip ifInsider net selling exceeds $5M over a rolling 90 days.
- P2Large Analyst Target Upside
Trip ifAnalyst target falls below $20 from current $30.80.
- P3Weak Quality And Losses
Trip ifOperating margin falls below -60% from current -39.6%.
- P4Negative Price Momentum
Trip ifShare price falls below the $12.56 stop level, more than 7% under the current $13.50.
- P5Earnings Event Risk
Trip ifEPS miss exceeds 100% of the estimate in the next 2 reports.